CS228523B2 - Process for the production of nasal powder form with increased resorpability and alkaloid content of type ergot peptides - Google Patents

Process for the production of nasal powder form with increased resorpability and alkaloid content of type ergot peptides Download PDF

Info

Publication number
CS228523B2
CS228523B2 CS817502A CS750281A CS228523B2 CS 228523 B2 CS228523 B2 CS 228523B2 CS 817502 A CS817502 A CS 817502A CS 750281 A CS750281 A CS 750281A CS 228523 B2 CS228523 B2 CS 228523B2
Authority
CS
Czechoslovakia
Prior art keywords
hydrogen
methyl
hydrogen atom
isopropyl
formula
Prior art date
Application number
CS817502A
Other languages
Czech (cs)
English (en)
Inventor
A G Sandoz
Original Assignee
Azria Moise Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azria Moise Dr filed Critical Azria Moise Dr
Publication of CS228523B2 publication Critical patent/CS228523B2/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01D—MEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
    • G01D2207/00—Indexing scheme relating to details of indicating measuring values
    • G01D2207/10—Displays which are primarily used in aircraft or display aircraft-specific information

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CS817502A 1976-11-19 1977-11-18 Process for the production of nasal powder form with increased resorpability and alkaloid content of type ergot peptides CS228523B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1457576 1976-11-19
CH698977 1977-06-07

Publications (1)

Publication Number Publication Date
CS228523B2 true CS228523B2 (en) 1984-05-14

Family

ID=25700540

Family Applications (2)

Application Number Title Priority Date Filing Date
CS817502A CS228523B2 (en) 1976-11-19 1977-11-18 Process for the production of nasal powder form with increased resorpability and alkaloid content of type ergot peptides
CS777615A CS228502B2 (en) 1976-11-19 1977-11-18 Method for the production of an application form with increased resorpability containing alkaloide

Family Applications After (1)

Application Number Title Priority Date Filing Date
CS777615A CS228502B2 (en) 1976-11-19 1977-11-18 Method for the production of an application form with increased resorpability containing alkaloide

Country Status (27)

Country Link
US (2) US4462983A (no)
JP (1) JPS5366440A (no)
AT (1) AT368881B (no)
AU (1) AU520754B2 (no)
CA (1) CA1103585A (no)
CS (2) CS228523B2 (no)
CY (1) CY1266A (no)
DE (2) DE2750090A1 (no)
DK (1) DK153440C (no)
ES (1) ES464275A1 (no)
FI (1) FI773376A (no)
FR (1) FR2371454A1 (no)
GB (1) GB1592563A (no)
GR (1) GR65229B (no)
HK (1) HK85984A (no)
HU (1) HU185924B (no)
IE (1) IE46167B1 (no)
IL (1) IL53419A (no)
KE (1) KE3453A (no)
MY (1) MY8400055A (no)
NL (1) NL187892C (no)
NO (1) NO773839L (no)
NZ (1) NZ185711A (no)
PH (1) PH23643A (no)
PT (1) PT67292B (no)
SE (1) SE451944B (no)
SG (1) SG61784G (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
US4284648A (en) * 1979-08-03 1981-08-18 The University Of Kentucky Research Foundation Nasal administration of propranolol
CH649300A5 (de) * 1981-08-07 1985-05-15 Sandoz Ag Ergopeptinderivate, ihre herstellung und verwendung.
FI81258C (fi) * 1982-02-01 1990-10-10 Sandoz Ag Foerfarande foer framstaellning av en farmaceutisk komposition foer nasal administration.
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
GB8413795D0 (en) * 1984-05-30 1984-07-04 Sandoz Ltd Organic compounds
GB8426922D0 (en) * 1984-10-24 1984-11-28 Sandoz Ltd Galenic formulation
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
FR2628638B1 (fr) * 1985-03-06 1992-12-18 Sandoz Lab Dispositif de pulverisation par voie nasale d'une dose unitaire de medicament en solution
JPS61263918A (ja) * 1985-05-16 1986-11-21 Banyu Pharmaceut Co Ltd 経皮吸収用製剤
AU587472B2 (en) * 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US4782047A (en) * 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
DE3710216A1 (de) * 1987-03-27 1988-10-06 Rentschler Arzneimittel Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen
DE68915203T2 (de) * 1988-03-22 1994-09-22 Fisons Plc, Ipswich, Suffolk Pharmazeutische Mischungen.
US4929640A (en) * 1988-04-04 1990-05-29 George D. McAdory Medicaments intended for combined use in the improvement of lymphocyte function
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
ES2177544T3 (es) * 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
WO1993025193A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Pharmaceutical preparation for intra-airway administration
ES2194867T3 (es) * 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
ES2197212T3 (es) * 1994-12-22 2004-01-01 Astrazeneca Ab Preparacion terapeutica para inhalacion que contiene la hormona paratiroidea, pth.
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
MXPA02007052A (es) * 2000-01-20 2002-12-13 Basilea Pharmaceutica Ag Composiciones que se administran nasalmente y que contienen peptidos ciclicos.
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
GB0208742D0 (en) * 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB2405334B (en) * 2002-04-17 2006-02-15 Nektar Therapeutics Uk Ltd Particulate materials
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
US20120000941A1 (en) * 2010-06-30 2012-01-05 Inspire Pharmaceuticals, Inc. Medicine dispenser
NZ741171A (en) 2015-09-10 2022-01-28 Impel Neuropharma Inc In-line nasal delivery device
EP3648738A1 (en) * 2017-07-02 2020-05-13 Dr. Reddy's Laboratories Limited Nasal dosage forms of dihydroergotamine
CN111936140A (zh) 2018-01-05 2020-11-13 英倍尔药业股份有限公司 通过精密鼻装置的双氢麦角胺的鼻内递送
EP3893877A4 (en) 2018-12-11 2022-09-14 Satsuma Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OR PREVENTION OF HEADACHE
GB2581431A (en) * 2018-12-11 2020-08-19 Satsuma Pharmaceuticals Inc Compositions, devices, and methods for treating or preventing headaches

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1063512A (en) * 1962-11-30 1967-03-30 Benger Lab Ltd Aerosols
GB1175430A (en) * 1966-04-07 1969-12-23 Sandoz Ltd Pharmaceutical Compositions containing Ergot Alkaloids
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
CH534683A (de) * 1970-05-26 1973-03-15 Sandoz Ag Verfahren zur Herstellung neuer Mutterkornpeptidalkaloide
US4076715A (en) * 1972-09-26 1978-02-28 Sandoz Ltd. 13-Bromo lysergic acid compounds
CA990287A (en) * 1972-09-26 1976-06-01 Sandoz Patents Limited 13-bromo-lysergic acid compounds
NL7314066A (no) * 1972-10-18 1974-04-22
US3896228A (en) * 1973-03-15 1975-07-22 Sandoz Ltd Method for treating nephrises
US3883655A (en) * 1973-10-11 1975-05-13 Sandoz Ltd Ergocornine or 2-bromo-{60 -ergocyptine in the treatment of parkinsonism
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
EP0119493A1 (en) * 1983-03-16 1984-09-26 American Cyanamid Company Use of copolymers of 2-acrylamido-2-methylpropane sulfonic acid for improving retention and dewatering in the manufacture of paper

Also Published As

Publication number Publication date
DE2802113A1 (de) 1979-07-26
JPS5366440A (en) 1978-06-13
AU3078377A (en) 1979-05-24
FR2371454B1 (no) 1980-08-22
ATA825477A (de) 1982-04-15
HU185924B (en) 1985-03-28
SG61784G (en) 1985-03-15
FI773376A (fi) 1978-05-20
US4758423A (en) 1988-07-19
IE46167B1 (en) 1983-03-09
ES464275A1 (es) 1978-12-16
NO773839L (no) 1978-05-22
IL53419A0 (en) 1978-01-31
FR2371454A1 (fr) 1978-06-16
US4462983A (en) 1984-07-31
PT67292B (fr) 1979-11-12
SE7712693L (sv) 1978-05-20
DK153440B (da) 1988-07-18
PH23643A (en) 1989-09-27
JPS6313965B2 (no) 1988-03-29
NL7712552A (nl) 1978-05-23
KE3453A (en) 1984-10-05
IL53419A (en) 1982-04-30
AU520754B2 (en) 1982-02-25
AT368881B (de) 1982-11-25
HK85984A (en) 1984-11-16
NL187892C (nl) 1992-02-17
CS228502B2 (en) 1984-04-16
PT67292A (fr) 1977-12-01
NL187892B (nl) 1991-09-16
SE451944B (sv) 1987-11-09
DK499477A (da) 1978-05-20
DE2750090A1 (de) 1978-06-01
CA1103585A (en) 1981-06-23
GB1592563A (en) 1981-07-08
MY8400055A (en) 1984-12-31
DK153440C (da) 1989-01-02
IE46167L (en) 1978-05-19
GR65229B (en) 1980-07-30
NZ185711A (en) 1980-04-28
CY1266A (en) 1984-11-23

Similar Documents

Publication Publication Date Title
CS228523B2 (en) Process for the production of nasal powder form with increased resorpability and alkaloid content of type ergot peptides
AU775588B2 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
JP4311369B2 (ja) ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物
PL183789B1 (pl) Kompozycje farmaceutyczne o przedłużonym działaniu, sposób ich wytwarzania i bromek (endo,syn)-(-)-3-(3-hydroksy-1-okso-2-fenylopropoksy) 8-metylo-8-(1-metyloetylo)-8-azonia bicyklo [3,2,1] oktanu
CZ114093A3 (en) Sulfate of 3-£2-(dimethylamino)ethyl-n-methyl-1h-indole-5-methane sulfonamide, and pharmaceutical preparations containing thereof
NZ254945A (en) Inhalation powder containing an antistatic agent in the carrier
JP2002509883A (ja) フマル酸アルキル水素エステルからなる乾癬、乾癬性関節炎、神経皮膚炎および限局性回腸炎クローン病の治療剤
HU198385B (en) Process for producing peroral pharmaceutical compositions containing acid-sensitive benzimidazol derivatives for treating gastrointestinal illnesses
AU2006275137A1 (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
JPS6089435A (ja) 狭心症発作抑制用吸入剤
JPH08504201A (ja) 抗うつ作用を有する医薬組成物としての２‐アミノ‐６‐ｎ‐プロピル‐アミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールの使用
CA2591406A1 (en) Pharmaceutical compounds and compositions
EA025287B1 (ru) Применение гликопирролата для лечения тахикардии
JP2003527412A (ja) 安定化された乾燥粉末製剤
IE914498A1 (en) Treatment of cystic fibrosis and pharmaceutical compositions¹for use therein
SK8652002A3 (en) Suspension comprising oxcarbazepine
US20030064031A1 (en) Use of a combination of compounds in a dry powder inhaler
US20100197719A1 (en) Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20020019420A1 (en) Methods and compositions for treating gastric disorders using optically pure (+)-pantoprazole
NZ196950A (en) Pharmaceutical compositions containing 1,3-bis-(2-carboxychromon-5-yl-oxy)propan-2-ol and a bronchodilator
JPH0532635A (ja) ヒスタミン誘導体の治療への応用と、新規なヒスタミン誘導体と、この誘導体の医薬としての使用
JPS6160815B2 (no)
US4039668A (en) Corticoid-containing inhalants
IT9022104A1 (it) Composizioni per la terapia mucolitica
Watanabe et al. Overview: pharmacotherapeutic considerations in the elderly psychiatric patient